In:
Arteriosclerosis, Thrombosis, and Vascular Biology, Ovid Technologies (Wolters Kluwer Health), Vol. 29, No. 12 ( 2009-12), p. 2117-2124
Abstract:
The endogenous NO synthase inhibitor and cardiovascular risk factor ADMA inhibits angiogenesis. We show for the first time that ADMA inhibits VEGF-induced endothelial cell motility and angiogenesis by modulating NO-dependent Rho GTPase activity. Further, normal angiogenic responses to VEGF are restored by overexpression of DDAH or active Rac1.
Type of Medium:
Online Resource
ISSN:
1079-5642
,
1524-4636
DOI:
10.1161/ATVBAHA.109.194035
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2009
detail.hit.zdb_id:
1494427-3
